09:04 AM EST, 01/29/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Wednesday it has entered into a collaboration and supply agreement with BeiGene to conduct a phase 3 clinical trial combining BeiGene's tislelizumab and ImmunityBio's ( IBRX ) Anktiva as a potential therapy for the advanced or metastatic non-small cell lung cancer in patients who have acquired resistance to immune checkpoint inhibitors therapy.

Financial terms of the collaboration weren't disclosed.

ImmunityBio ( IBRX ) said it will conduct the confirmatory phase 3 trial across multiple sites and among 462 participants.

The primary endpoint of the study is overall survival, while secondary endpoints include disease control rate, progression-free survival, objective response rate, and safety, the company said.